Back

CB2R-induced differentiation epigenetically restrains cancer plasticity enabling adaptive therapy

Salazar-Roa, M.; G. Martinez-Illescas, N.; Perez-Garcia, G.; Rubert-Hernandez, M.; Quezada-Gutierrez, C.; Martin-Zapater, E.; Alonso-Colmenar, L. M.; Hernandez, C.; Zarco-Cuadrillero, A.; Caleiras, E.; Munoz, M.; Payo-Payo, A.; Frias-Aldeguer, L.; Sanchez, C.; Balcells-Camps, M.; Edelman, E. R.

2025-08-01 cancer biology
10.1101/2025.07.29.667375 bioRxiv
Show abstract

Cellular plasticity enables cancer cells to escape therapy by adopting stem-like or alternate lineage states. Here, we identify a mechanism by which cannabinoid receptor 2 (CB2R) activation promotes irreversible lineage commitment in breast cancer. Using patient-derived and murine organoids, we show that brief, low-dose exposure to CB2R agonists--either phytogenic or synthetic--induces a basal-to-luminal transition, accompanied by reduced self-renewal, invasiveness, and tumor-initiating potential. These changes are retained under conditions that normally promote dedifferentiation, including fibroblast co-culture, immune pressure, and mechanical shear stress. Mechanistically, CB2R engagement initiates a transient chromatin remodeling program, marked by early expression of pluripotency-associated genes followed by silencing and differentiation commitment. This epigenetically stabilized state renders tumor cells more responsive to tamoxifen and limits the emergence of resistant clones. Our findings uncover a previously unrecognized role for CB2R in modulating cancer cell identity and suggest new opportunities to constrain tumor plasticity by directing differentiation through a drug-responsive pathway.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.